Just over an hour later, the New England Journal of Medicine retracted a separate study, focused on blood pressure medications in Covid-19, that relied on data from the same company.
The retractions came at the request of the authors of the studies, published last month, who were not directly involved with the data collection and sources, the journals said.
"We can no longer vouch for the veracity of the primary data sources," Mandeep Mehra of Brigham and Women's Hospital, Frank Ruschitzka of University Hospital Zurich, and Amit Patel of University of Utah said in a statement issued by the Lancet. "Due to this unfortunate development, the authors request that the paper be retracted."
The retraction of the Lancet paper is sure to add fuel to contentious arguments about the potential of chloroquine and hydroxychloroquine, two old malaria drugs, in Covid-19, the disease caused by the novel coronavirus. President Trump has touted them as valuable treatments, despite a lack of rigorous data showing they have a benefit.
Comment: One wonders if the authors of this article even did any research:
- Global survey reveals hydroxychloroquine rated 'most effective therapy' by doctors for coronavirus
- Study on early hydroxychloroquine treatment of COVID-19 patients shows 98.7% cure rate
- Los Angeles doctor reports remarkable success treating COVID-19 patients with hydroxychloroquine & zinc
- Results from a controlled trial of hydroxychloroquine for COVID-19
- Hydroxychloroquine rated 'most effective' coronavirus treatment, poll of doctors finds
- Bahrain, Belgium successfully treating coronavirus with hydroxychloroquine
- Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial - Renmin Hospital, Wuhan
- Association of American Physicians and Surgeons: Hydroxychloroquine has about 90 percent chance of helping COVID-19 patients
- Dr. Vladimir Zelenko has now treated 699 coronavirus patients with 100% success using Hydroxychloroquine Sulfate, Zinc and Z-Pak
Meanwhile, on Wednesday, researchers reported the results of the first gold-standard clinical trial of hydroxycholoroquine in Covid-19, concluding that it did not prevent infections any better than placebo. Other clinical trials, including some looking at the drugs as treatments, are ongoing.
The Lancet study gained so much attention because it went further than other observational studies that had similarly found the drugs were not associated with improved outcomes for patients. The study, which was purportedly based on patient data from 671 hospitals on six continents, reported the drugs also corresponded to higher mortality.
The findings led to the pause of some global clinical trials studying hydroxychloroquine so researchers could check for any safety concerns. Outside experts, however, quickly raised concerns after noticing inconsistencies in the data. They asked the company that compiled and analyzed the data, Surgisphere, to explain how it sourced its data.
As scrutiny grew, the authors on the paper not affiliated with Surgisphere called for an independent audit. In their Lancet statement Thursday, they said that Surgisphere was not cooperating with the independent reviewers and would not provide the data.
"As such, our reviewers were not able to conduct an independent and private peer review and therefore notified us of their withdrawal from the peer-review process," the researchers wrote.
Comment: See also: Governments And WHO Changed Covid-19 Policy Based on Suspect Data From Tiny US Company